Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kotzsch, Matthias ^a   Magdolen, Viktor ^b   Greither, Thomas ^c   Kappler, Matthias ^c   Bache, Matthias ^c   Lautenschläger, Christine ^c   Füssel, Susanne ^a   Eckert, Alexander W ^c   Luther, Thomas ^a,d   Baretton, Gustavo ^a   Würl, Peter ^e   Taubert, Helge ^f  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d Medical Laboratory Unit   (Germany)

^e UNIVERSITY OF BREMEN   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; UROKINASE; UROKINASE RECEPTOR; ISOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATED SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC RISK; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RNA SPLICING; SOFT TISSUE SARCOMA; ALTERNATIVE RNA SPLICING; CANCER STAGING; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; STATISTICS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN ISOFORMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA; SURVIVAL ANALYSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 79959457472     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-273     Document Type: Article

References (42)

1. Enzinger FM, Weiss SW. General considerations. Soft Tissue Tumors 1995, 1-16. St Louis, Missouri: Mosby, Enzinger FM, Weiss SW.
2. Giuliano AE, Eilber FR. The rationale for planned reoperation after unplanned total excision of soft-tissue sarcoma. J Clin Oncol 1985, 3:1344-1348.
3. Chang AE, Sondak VK. Clinical evaluation and treatment of soft tissue tumors. Soft Tissue Tumors 1995, 17-38. St Louis, Missouri: Mosby, Enzinger FM, Weiss SW.
4. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults: Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993, 217:72-77. 10.1097/00000658-199301000-00012, 1242736, 8424704.
5. Potter DA, Glenn J, Kinsella T. Patterns of recurrence in patients with high grade soft-tissue sarcomas. J Clin Oncol 1985, 3:353-358.
6. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008, 214:283-293. 10.1002/path.2282, 18095256.
7. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008, 36:184-194.
8. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004, 25:450-455. 10.1016/j.it.2004.06.004, 15275645.
9. Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N, Schmitt M. Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010, 10:947-962. 10.1586/erm.10.73, 20964613.
10. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34:122-136. 10.1016/j.ctrv.2007.10.005, 18162327.
11. Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010, 10:1051-1067. 10.1586/erm.10.71, 21080821.
12. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004, 24:13-39. 10.1002/med.10054, 14595671.
13. Hoyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007, 44:65-102.
14. Luther T, Kotzsch M, Meye A, Langerholc T, Füssel S, Olbrich N, Albrecht S, Ockert D, Muehlenweg B, Friedrich K, Grosser M, Schmitt M, Baretton G, Magdolen V. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost 2003, 89:705-717.
15. Kotzsch M, Farthmann J, Meye A, Füssel S, Baretton G, Tjan-Heijnen VCG, Schmitt M, Luther T, Sweep FCGJ, Magdolen V, Span PN. Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer 2005, 41:2760-2768. 10.1016/j.ejca.2005.09.002, 16256342.
16. Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Füssel S, Meijer-van Gelder ME, Smid M, Schmitt M, Baretton G, Luther T, Magdolen V, Foekens JA. Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat 2008, 111:229-240. 10.1007/s10549-007-9782-6, 17952591.
17. Sato S, Kopitz C, Grismayer B, Beaufort N, Reuning U, Schmitt M, Luther T, Kotzsch M, Krüger A, Magdolen V. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2011, 127:649-657. 10.1007/s10549-010-1042-5, 20635136.
18. Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. Anticancer Res 2000, 20:3031-3036.
19. Choong PF, Fernö M, Akerman M, Willén H, Långström E, Gustafson P, Alvegård T, Rydholm A. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 1996, 69:268-272. 10.1002/(SICI)1097-0215(19960822)69:4<268::AID-IJC5>3.0.CO;2-V, 8797866.
20. Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M. Co-detection of members of the urokinase plasminogen activator system in tumor tissue and in serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 2010, 102:731-737. 10.1038/sj.bjc.6605520, 2837565, 20051950.
21. Benassi MS, Ponticelli F, Azzoni E, Gamberi G, Pazzaglia L, Chiechi A, Conti A, Spessotto P, Scapolan M, Pignotti E, Bacchini P, Picci P. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas. Histol Histopathol 2007, 22:1017-1024.
22. Würl P, Kappler M, Meye A, Bartel F, Köhler T, Lautenschläger C, Bache M, Schmidt H, Taubert H. Co-expression of survivin and TERT and risk of tumor-related death in patients with soft-tissue sarcoma. Lancet 2002, 359:943-945. 10.1016/S0140-6736(02)07990-4, 11918915.
23. Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FCGJ, Span PN, Schmitt M, Magdolen V. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Medicine 2008, 21:251-259.
24. Schmidt U, Fuessel S, Koch R, Baretton G, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006, 66:1521-1534. 10.1002/pros.20490, 16921506.
25. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998, 228:355-365. 10.1097/00000658-199809000-00008, 1191491, 9742918.
26. Harbeck N, Kates R, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004, 91:450-456.
27. Schmitt M, Lienert S, Prechtel D, Sedlaczek E, Welk A, Reuning U, Magdolen V, Jänicke F, Sweep CGJ, Harbeck N. The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations. J Clinical Ligand Assay 2002, 25:43-52.
28. Spyratos F, Bouchet C, Tozlu S, Labroquere M, Vignaud S, Becette V, Lidereau R, Bieche I. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res 2002, 22:2997-3003.
29. Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 2006, 24:4245-4253. 10.1200/JCO.2005.05.1912, 16963728.
30. Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb Res 2007, 120:753-762. 10.1016/j.thromres.2006.12.016, 17258797.
31. Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008, 36:160-167. 10.1097/MPA.0b013e31815750f0, 18376307.
32. Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999, 17:3048-3057.
33. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000, 60:636-643.
34. Castelló R, Estellés A, Vázquez C, Falcó C, España F, Almenar SM, Fuster C, Aznar J. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin Chem 2002, 48:1288-1295.
35. Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumor tissue of patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol 2010, 136:1709-1718. 10.1007/s00432-010-0829-4, 20204407.
36. Nagamine Y, Medcalf RL, Muñoz-Cánoves P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 2005, 93:661-675.
37. Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldmann FM, Ponder BA, Werb Z. Prognostic value of PAI-1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI-1 expression. Cancer Epidemiol Biomarkers Prev 2006, 15:2107-2114. 10.1158/1055-9965.EPI-06-0351, 2731792, 17119035.
38. Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A, Mougin B. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 2006, 6:216. 10.1186/1471-2407-6-216, 1564186, 16945123.
39. Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH, Song SK, Kim HS. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology 2004, 66:210-217. 10.1159/000077997, 15218312.
40. Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, Smith RC. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol 2005, 20:256-263. 10.1111/j.1440-1746.2004.03531.x, 15683429.
41. Kita Y, Fukagawa T, Mimori K, Kosaka Y, Ishikawa K, Aikou T, Natsugoe S, Sasako M, Mori M. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Br J Cancer 2009, 100:153-159. 10.1038/sj.bjc.6604806, 2634681, 19050704.
42. Warnecke-Eberz U, Prenzel KL, Baldus SE, Metzger R, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer. Pancreas 2008, 36:173-177. 10.1097/MPA.0b013e31815ac538, 18376309.